{"id":1400,"date":"2024-05-10T15:17:16","date_gmt":"2024-05-10T13:17:16","guid":{"rendered":"https:\/\/www.incipit-pediatric.net\/trials\/novartis-orion-19-20\/"},"modified":"2024-05-10T15:58:49","modified_gmt":"2024-05-10T13:58:49","slug":"novartis-orion-19-20","status":"publish","type":"trials","link":"https:\/\/www.incipit-pediatric.net\/en\/trials\/novartis-orion-19-20\/","title":{"rendered":"Novartis Orion 19-20"},"content":{"rendered":"<p class=\"x_MsoNormal\"><strong>Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2] randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (2 to less than 12 years) with homozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-19<\/strong>)<\/p>\n<p class=\"x_MsoNormal\">Two-part randomized multicenter study (double-blind inclisiran versus placebo wpcodeself followed by open-label inclis[Anno 1]iran wpcodeself).[Anno 2]<\/p>\n<p class=\"x_MsoNormal\">Two-part randomized multicenter study (double-blind inclisiran versus placebo [Year 1] followed by open-label study with inclisiran [Year 2]) for[Anno 2][Anno 1]<\/p>\n<p class=\"x_MsoNormal\">evaluate the safety, tolerability and efficacy of inclisiran in children (2 to less than 12 years) to less than 12 years) with homozygous familial hypercholesterolemia and<\/p>\n<p class=\"x_MsoNormal\">with heterozygous familial hypercholesterolemia with elevated LDL cholesterol (ORION 19-20)<\/p>\n<p class=\"x_MsoNormal\">It is a multicenter, phase III study designed to evaluate the safety, tolerability and efficacy of inclisiran in children (aged 2 to &lt;12 years) with homozygous familial hypercholesterolemia (HoFH) and heterozygous familial hypercholesterolemia (HeFH) with low lipoprotein cholesterol. density (LDL) high.&lt; The use of inclisiran for the treatment of HoFH in children will be studied in order to obtain the necessary pediatric information on inclisiran.<\/p>\n<p class=\"x_MsoNormal\">\n","protected":false},"excerpt":{"rendered":"<p>Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2] randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (2 to less than 12 years) with homozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-19) Two-part randomized multicenter study (double-blind inclisiran versus placebo wpcodeself followed by open-label inclis[Anno 1]iran [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"class_list":["post-1400","trials","type-trials","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.incipit-pediatric.net\/en\/wp-json\/wp\/v2\/trials\/1400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.incipit-pediatric.net\/en\/wp-json\/wp\/v2\/trials"}],"about":[{"href":"https:\/\/www.incipit-pediatric.net\/en\/wp-json\/wp\/v2\/types\/trials"}],"wp:attachment":[{"href":"https:\/\/www.incipit-pediatric.net\/en\/wp-json\/wp\/v2\/media?parent=1400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}